Jason Tardio - Apr 8, 2022 Form 4 Insider Report for Ovid Therapeutics Inc. (OVID)

Role
Chief Operating Officer
Signature
/s/ Danielle Mann for Jason Tardio by PoA
Stock symbol
OVID
Transactions as of
Apr 8, 2022
Transactions value $
$0
Form type
4
Date filed
4/12/2022, 05:40 PM
Previous filing
Feb 4, 2022
Next filing
Sep 14, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OVID Stock Option (Right to Buy) Award $0 +87.5K $0.00 87.5K Apr 8, 2022 Common Stock 87.5K $3.22 Direct F1
transaction OVID Stock Option (Right to Buy) Award $0 +10K $0.00 10K Apr 8, 2022 Common Stock 10K $3.22 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option shall vest as follows: 25% of the shares subject to the option will vest and become exercisable October 8, 2022 and the remaining shares will vest in 18 equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date.
F2 The option shall vest as follows: 25% of the shares subject to the option will vest and become exercisable on April 8, 2023 and the remaining shares will vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous services through such vesting date.